Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02152774
Other study ID # 14.12
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received May 23, 2014
Last updated April 23, 2015
Start date May 2014

Study information

Verified date April 2015
Source New York Glaucoma Research Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months.

Secondary Outcome

Secondary objectives are:

1. To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular pressure (IOP).

2. To evaluate the long term effect of the drug on IOP.

3. To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria:

1. Patients between 50 and 85 years old; of either sex.

2. Patients with CACG with =180° PAS

3. IOP =22 mmHg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart

4. No previous intraocular surgery except clear cornea phacoemulsification.

5. Corrected visual acuity in both eyes =20/50 in the eligible eye

6. Not more than 6 diopters spherical equivalent on the study eye

7. Not more than 3 diopters cylinder equivalent on the study eye

8. Have given written informed consent, prior to any investigational procedures.

9. Ability to attend for the 6-month duration of the study

Exclusion Criteria:

1. Open angle glaucoma

2. Closed angle glaucoma with <180° PAS

3. Intraocular pressure >35 mmHg

4. Severe glaucomatous damage

5. Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.

6. Previous intraocular surgery except clear cornea phacoemulsification.

7. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study.

8. Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or drops for treatment of dry eye syndrome (which may be used throughout the study).

9. Any abnormality preventing reliable applanation tonometry of either eye.

10. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.

11. Changes of systemic medication that could have a substantial effect on IOP anticipated during the study.

12. Participation in any investigational study within the past 30 days.

13. Inability to perform reliable VF testing.

14. Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.

15. Self-reported poor compliance to treatment.

16. Reluctance to return for scheduled follow-up visits.

17. Patients not able to understand the nature of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Rho-Kinase Inhibitor


Locations

Country Name City State
United States Glaucoma Associates of New York New York New York

Sponsors (1)

Lead Sponsor Collaborator
New York Glaucoma Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Long Lasting effect of study drug to reduce IOP To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with CACG treated for 6 months. 6 Months Yes
Secondary Secondary Outcome To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP. 6 Months Yes